WASHINGTON, Feb. 2, 2018 /PRNewswire-USNewswire/ -- The Pharmaceutical Care Management Association (PCMA) released the following statement on the Centers for Medicare and Medicaid's (CMS) 2019 Medicare Advantage and Part D Advance Notice Part II and Draft Call Letter:
"By proposing to allow plans to implement a seven-day limit on certain opioids, CMS is taking an important step in the fight against opioid abuse. The next even more impactful step is for Congress to pass legislation (H.R. 3528, the 'Every Prescription Conveyed Securely Act') requiring e-prescribing of controlled substances in Medicare.
PCMA looks forward to working with Secretary of Health & Human Services Alex Azar and Food and Drug Administration Commissioner Dr. Scott Gottlieb on these and other policy solutions to address the opioid crisis."
Last year, PCMA submitted a set of policy solutions on the opioid crisis to Commissioner Gottlieb, including:
- Require E-prescribing (e-Rx) for Controlled Substances
- Seven-Day Opioid Prescription Limits for Acute Pain
- Endorse the CDC's Guideline for Prescribing Opioids for Chronic Pain
- Improve and Integrate State Prescription Drug Monitoring Programs (PDMPs) and Require Prescribers to Check PDMPs
- Give Medicare Part D Plans More Tools to Fight Pharmacy Opioid Fraud
- Achieve Timely and Flexible Implementation of the Comprehensive Addiction and Recovery Act (CARA) Lock-In
PCMA is the national association representing America's pharmacy benefit managers (PBMs). PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, Medicaid plans, and others.
SOURCE Pharmaceutical Care Management Association
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article